PE20060467A1 - Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos - Google Patents

Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos

Info

Publication number
PE20060467A1
PE20060467A1 PE2005000490A PE2005000490A PE20060467A1 PE 20060467 A1 PE20060467 A1 PE 20060467A1 PE 2005000490 A PE2005000490 A PE 2005000490A PE 2005000490 A PE2005000490 A PE 2005000490A PE 20060467 A1 PE20060467 A1 PE 20060467A1
Authority
PE
Peru
Prior art keywords
administration
hemorrhage
disruption
treatment
ethnylestradiol
Prior art date
Application number
PE2005000490A
Other languages
English (en)
Inventor
Andreas Sachse
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060467(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20060467A1 publication Critical patent/PE20060467A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

REFERIDA A UN METODO ANTICONCEPTIVO HORMONAL FEMENINO, QUE CONSISTE EN LA ADMINISTRACION MONOFASICA CONTINUA DE UNA PREPARACION ACTIVA DE ETNILESTRADIOL EN UNA CANTIDAD DE 5 A 30 MICROGRAMOS, O DE OTRO ESTROGENO SINTETICO O NATURAL EN UNA CANTIDAD EQUIVALENTE A 5 A 30 MICROGRAMOS DE ETINILESTRADIOL DIARIOS, Y UN PROGESTAGENO EN UNA CANTIDAD ANTICONCEPTIVA PARA LA MUJER DURANTE UN PERIODO MINIMO, DESPUES DEL CUAL LA MUJER INICIA UN INTERVALO DE 1 A 6 DIAS DE DICHA ADMINISTRACION DE DICHA PREPARACION ACTIVA, Y DONDE DICHO INTERVALO ES SEGUIDO POR AL MENOS UN CICLO ULTERIOR DE ADMINISTRACION CUYA DURACION ES AL MENOS IGUAL A LA DEL PRIMER PERIODO. ESTE REGIMEN EXTENDIDO FLEXIBLE PARA LA ANTICONCEPCION HORMONAL ES UTIL PARA TRATAR PROBLEMAS DE HEMORRAGIAS ASOCIADOS CON EL USO EXTENDIDO FIJO DE ANTICONCEPTIVOS HORMONALES
PE2005000490A 2004-04-30 2005-05-03 Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos PE20060467A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56644304P 2004-04-30 2004-04-30
US57502404P 2004-05-28 2004-05-28
US57719904P 2004-06-07 2004-06-07
US63838004P 2004-12-27 2004-12-27
US66006805P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
PE20060467A1 true PE20060467A1 (es) 2006-06-11

Family

ID=35056905

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000490A PE20060467A1 (es) 2004-04-30 2005-05-03 Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos

Country Status (29)

Country Link
US (3) US8163721B2 (es)
EP (1) EP1747001B1 (es)
JP (4) JP2007535519A (es)
KR (4) KR20070004919A (es)
CN (1) CN103127156A (es)
AR (1) AR048722A1 (es)
AU (1) AU2005237255B2 (es)
BR (1) BRPI0510493A (es)
CA (1) CA2562296A1 (es)
CR (1) CR8709A (es)
DK (1) DK1747001T3 (es)
EA (2) EA031227B1 (es)
EC (1) ECSP066999A (es)
ES (1) ES2704999T3 (es)
HU (1) HUE041475T2 (es)
IL (1) IL178458A (es)
LT (1) LT1747001T (es)
MX (1) MXPA06012567A (es)
MY (1) MY151322A (es)
NO (1) NO341685B1 (es)
NZ (1) NZ586107A (es)
PA (1) PA8631801A1 (es)
PE (1) PE20060467A1 (es)
SG (2) SG152288A1 (es)
SI (1) SI1747001T1 (es)
SV (1) SV2006002100A (es)
TW (1) TWI374735B (es)
UY (1) UY28875A1 (es)
WO (1) WO2005105103A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20070088010A1 (en) * 2005-10-17 2007-04-19 Doris Huebler Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
GB2475013A (en) * 2008-09-16 2011-05-04 Playtex Products Llc Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administrating same
ES2734510T3 (es) 2008-10-08 2019-12-10 Agile Therapeutics Inc Administración transdérmica
WO2010042610A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
EP2343979B1 (en) 2008-10-08 2020-04-08 Agile Therapeutics, Inc. Transdermal delivery
WO2010111488A1 (en) 2009-03-27 2010-09-30 Agile Therapeutics, Inc. Transdermal delivery
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
ES2877186T3 (es) 2015-06-18 2021-11-16 Estetra Sprl Comprimido orodispersable que contiene estetrol
LT3310346T (lt) 2015-06-18 2021-06-10 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
GEP20217243B (en) 2015-06-18 2021-04-26 Sprl Estetra Orodispersible dosage unit containing an estetrol component
TN2017000499A1 (en) 2015-06-18 2019-04-12 Mithra Pharmaceuticals S A Orodispersible dosage unit containing an estetrol component
CN108025014B (zh) * 2015-06-23 2021-10-22 莱昂实验室制药股份有限公司 用于过重女性患者的基于屈螺酮的避孕药
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
IL300580A (en) 2016-09-30 2023-04-01 Takeda Pharmaceuticals Co Methods for treating uterine fibroids and endometrial disease
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244096A (en) 1988-04-22 1993-09-14 Stoner Fred L Preventive treatment kit against sexually transmitted disease
AU3473193A (en) 1992-01-17 1993-08-03 Procter & Gamble Company, The Treatment for atherosclerosis
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5552394A (en) 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
CN1186024C (zh) * 1996-07-26 2005-01-26 惠氏公司 单阶段避孕方法和含有黄体酮和雌激素组合物的避孕药盒
US6451778B1 (en) 1996-07-26 2002-09-17 Wyeth Oral contraceptive
US5842441A (en) 1996-08-26 1998-12-01 Pharmalett Denmark A/S Medicated and individualized treatment shampoo for dermatological disturbances of companion animals
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
JP4354667B2 (ja) 1999-08-31 2009-10-28 バイエル・シエーリング・ファーマ・アクチエンゲゼルシャフト 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6653298B2 (en) * 2000-01-14 2003-11-25 Sterix Limited Composition
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
IL145876A0 (en) 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
US20020193356A1 (en) * 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
US20030018018A1 (en) 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US8501720B2 (en) 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea

Also Published As

Publication number Publication date
IL178458A0 (en) 2008-04-13
JP2015187157A (ja) 2015-10-29
KR20070004919A (ko) 2007-01-09
AU2005237255B2 (en) 2011-07-07
NZ586107A (en) 2012-05-25
ES2704999T3 (es) 2019-03-21
IL178458A (en) 2016-08-31
CA2562296A1 (en) 2005-11-10
TWI374735B (en) 2012-10-21
JP2007535519A (ja) 2007-12-06
US20050250747A1 (en) 2005-11-10
KR20150058555A (ko) 2015-05-28
MXPA06012567A (es) 2006-12-15
US20150174142A1 (en) 2015-06-25
SG152288A1 (en) 2009-05-29
WO2005105103A3 (en) 2006-09-08
ECSP066999A (es) 2006-12-29
EA200601908A1 (ru) 2007-04-27
SI1747001T1 (sl) 2019-02-28
US8163721B2 (en) 2012-04-24
EP1747001B1 (en) 2018-10-10
EP1747001A2 (en) 2007-01-31
EA031227B1 (ru) 2018-12-28
JP2013018787A (ja) 2013-01-31
BRPI0510493A (pt) 2007-11-13
KR101812160B1 (ko) 2017-12-27
KR20130022425A (ko) 2013-03-06
HUE041475T2 (hu) 2019-05-28
JP6153967B2 (ja) 2017-06-28
CN103127156A (zh) 2013-06-05
JP6134491B2 (ja) 2017-05-24
EA201200377A1 (ru) 2012-08-30
AR048722A1 (es) 2006-05-17
KR20160150113A (ko) 2016-12-28
EA016625B1 (ru) 2012-06-29
TW200603781A (en) 2006-02-01
US20120202779A1 (en) 2012-08-09
CR8709A (es) 2007-08-28
AU2005237255A1 (en) 2005-11-10
PA8631801A1 (es) 2006-11-09
DK1747001T3 (en) 2019-02-04
SV2006002100A (es) 2006-02-15
SG10201701904TA (en) 2017-05-30
NO20065499L (no) 2006-11-29
NO341685B1 (no) 2017-12-18
WO2005105103A2 (en) 2005-11-10
EA201200377A8 (ru) 2018-01-31
JP2017048253A (ja) 2017-03-09
LT1747001T (lt) 2019-01-25
MY151322A (en) 2014-05-15
UY28875A1 (es) 2005-11-30

Similar Documents

Publication Publication Date Title
PE20060467A1 (es) Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos
US10532025B2 (en) Intrauterine delivery system for contraception
PE20051038A1 (es) Uso extendido de combinacion que comprende estrogenos y progestinas
ES2561823T3 (es) Método de anticoncepción una vez al mes
GEP20105066B (en) Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
ES2281551T3 (es) Metodo de prevencion o tratamiento de enfermedades ginecologicas benignas.
PA8638601A1 (es) Regimenes y kits de progestina ciclica
BRPI0412493A (pt) métodos de tratamento hormonal utilizando regimes contraceptivos com administração contìnua de estrogênio
ECSP077131A (es) Regímenes y los juegos de anticonceptivos del antagonista del receptor de progesterona
AR054144A1 (es) Regimenes para anticonceptivos monofasicos orales
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
NZ591627A (en) Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
AR049197A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
CN105078642A (zh) 一种子宫内植入物
AR048806A1 (es) Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio
AR046762A1 (es) Hormonas de administracion transdermica que no necesitan potenciadores de penetracion
AR049195A1 (es) Uso de una combinacion de etinilestradiol y acetato de clormadinona para la preparacion de un medicamento
Gupta et al. Non-oral routes, novel formulations and devices of contraceptives: An update
CY1111406T1 (el) Χρηση βαλερικης οιστραδιολης ή οιστραδιολης σε συνδυασμο με διενογεστη για την απο του στοματος θεραπεια της αιμορραγιας λογω δυσλειτουργιας της μητρας με τη μορφη απο του στοματος αντισυλληψης
ES2295050T3 (es) Mesoprogestinas para el tratamiento y la prevencion de trastornos ginecologicos benignos dependientes de hormonas.
Adil et al. Laugier-Hunziker syndrome: a rare disease entity
CN201161051Y (zh) 宫腔粘连治疗器
Familiar Inês Gante
Prilepskaya et al. Emergency hormonal contraception (literature review)
Zañartu et al. Steroid release from polymer vaginal devices. Effect on fertility inhibition

Legal Events

Date Code Title Description
FC Refusal